Damien A. Leach

DX465701, 28 Woodville Road
Woodville South, SA 5011, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 37 publications

IRE1 activity is prognostic in localised and metastatic prostate cancer and affects epithelial lineage states.

IRE1 activity is prognostic in localised and metastatic prostate cancer and affects epithelial lineage states.

Journal: EMBO molecular medicine

Published: June 04, 2025

Disruption of androgen receptor-cofactor interactions by the RNA-binding protein FUS/TLS alters androgen signalling in prostate cancer.

Disruption of androgen receptor-cofactor interactions by the RNA-binding protein FUS/TLS alters androgen signalling in prostate cancer.

Journal: Oncogene

Published: May 07, 2025

Handheld ISFET Lab-on-Chip detection of YAP1 nucleic acid and AR-FL and AR-V7 mRNA from liquid biopsies for prostate cancer prognosis.

Handheld ISFET Lab-on-Chip detection of YAP1 nucleic acid and AR-FL and AR-V7 mRNA from liquid biopsies for prostate cancer prognosis.

Journal: Biosensors & bioelectronics

Published: January 13, 2025

Thieno[2,3-b]pyridine compounds potently inhibit prostate cancer growth and motility.

Thieno[2,3-b]pyridine compounds potently inhibit prostate cancer growth and motility.

Journal: Endocrine oncology (Bristol, England)

Published: December 16, 2024

Simultaneous inhibition of TRIM24 and TRIM28 sensitises prostate cancer cells to antiandrogen therapy, decreasing VEGF signalling and angiogenesis.

Simultaneous inhibition of TRIM24 and TRIM28 sensitises prostate cancer cells to antiandrogen therapy, decreasing VEGF signalling and angiogenesis.

Journal: Molecular oncology

Published: August 06, 2024

Androgen receptor modulatory miR-1271-5p can promote hormone sensitive prostate cancer cell growth.

Androgen receptor modulatory miR-1271-5p can promote hormone sensitive prostate cancer cell growth.

Journal: Frontiers in oncology

Published: May 29, 2024

Correction: The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer.

Correction: The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer.

Journal: British journal of cancer

Published: February 14, 2024

Apoptosis-modulatory miR-361-3p as a novel treatment target in endocrine-responsive and endocrine-resistant breast cancer.

Apoptosis-modulatory miR-361-3p as a novel treatment target in endocrine-responsive and endocrine-resistant breast cancer.

Journal: The Journal of endocrinology

Published: December 19, 2022

Liver Microenvironment Response to Prostate Cancer Metastasis and Hormonal Therapy.

Liver Microenvironment Response to Prostate Cancer Metastasis and Hormonal Therapy.

Journal: Cancers

Published: November 18, 2022

Epigenetic Coregulation of Androgen Receptor Signaling.

Epigenetic Coregulation of Androgen Receptor Signaling.

Journal: Advances in experimental medicine and biology

Published: September 15, 2022

Cellular specificity of androgen receptor, coregulators, and pioneer factors in prostate cancer.

Cellular specificity of androgen receptor, coregulators, and pioneer factors in prostate cancer.

Journal: Endocrine oncology (Bristol, England)

Published: August 26, 2022

The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer.

The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer.

Journal: British journal of cancer

Published: July 20, 2022

Showing 1-12 of 37

Last Updated: 09/26/2026